Oryzon Genomics S.A. (0RDB.L)

2.0200 +0.0400 (+2.02%) At close: 05:56PM BST

Oryzon Genomics S.A.

Sant Ferran 74
Cornellà de Llobregat 08940
Spain
34 93 515 13 13
https://www.oryzon.com

Sector(s): 
Industry: 
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Carlos Manuel Buesa Arjol	Co-Founder, Chairman, CEO & President	58k	N/A	N/A
Mr. Enric Rello Condomines	Director of Operations, COO & CFO	N/A	N/A	N/A
Mr. Jordi Xaus Pey	Chief Scientific Officer	N/A	N/A	N/A
Mr. Xavier Perpinya Ribera	Head of Internal Audit & Compliance	N/A	N/A	N/A
Mr. Emili Torrell Cortada	Chief Business Development Officer	N/A	N/A	N/A
Ms. Neus Virgili Bernado	Chief Intellectual Property Officer	N/A	N/A	N/A
Dr. Michael Thomas Ropacki Ph.D.	Chief Medical Officer of CNS	N/A	N/A	N/A
Ms. Sonia Paloma Gutierrez Bezon	Chief of Clinical Operations	N/A	N/A	N/A
Dr. Ana Limon	Senior Vice President of Clinical Development & Global Medical Affairs	N/A	N/A	N/A
Dr. Douglas V. Faller M.D., Ph.D.	Global Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2015, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

Corporate governance

Oryzon Genomics S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.